본문 바로가기
KERD
논문KCI 등재

의료분야에서 부패범죄의 양상과 대책 -의약품 리베이트(rebate)를 중심으로-

Patterns and measures of Corruption in Health care: A Focus on Pharmaceuticals Rebate

0

조회

0

다운로드

8

인용

0

참고문헌

키워드

주제분류법학

초록

A rebate is an amount paid by way of reduction, return, or refund on what has already been paid or contributed. It is a type of sales promotion marketers use primarily as incentives or supplements to product sales. But a rebate in drug manufacturers is not positive meanings but negative meanings. But Pharmaceuticals Rebate are deemed to be unethical practices of concerned sectors, threatens to distort the patient's right to choose, to waste health care budget of government. To crackdown on unlawful drug marketing activities, A new bill, which orders lowering drug prices when drug makers are caught for unfair trading, has been enforced 2010. In times past, there were no legal grounds to punish doctors and pharmacists for taking kickbacks in connection with drug transactions. An effective approach calls for dual punishment on both the giving and receiving ends of illegal rebates. To address this problem, lawmakers have proposed bills that would make doctors and pharmacists subject to punishment for taking illicit money. I expect that an exclusive prosecutor will respond to cases more promptly, imposing sanctions against them and pledging to eradicate illegal practices in the drug industry. Pharmaceutical companies should to refrain from using rebates as a marketing tool.

Abstract

A rebate is an amount paid by way of reduction, return, or refund on what has already been paid or contributed. It is a type of sales promotion marketers use primarily as incentives or supplements to product sales. But a rebate in drug manufacturers is not positive meanings but negative meanings. But Pharmaceuticals Rebate are deemed to be unethical practices of concerned sectors, threatens to distort the patient's right to choose, to waste health care budget of government. To crackdown on unlawful drug marketing activities, A new bill, which orders lowering drug prices when drug makers are caught for unfair trading, has been enforced 2010. In times past, there were no legal grounds to punish doctors and pharmacists for taking kickbacks in connection with drug transactions. An effective approach calls for dual punishment on both the giving and receiving ends of illegal rebates. To address this problem, lawmakers have proposed bills that would make doctors and pharmacists subject to punishment for taking illicit money. I expect that an exclusive prosecutor will respond to cases more promptly, imposing sanctions against them and pledging to eradicate illegal practices in the drug industry. Pharmaceutical companies should to refrain from using rebates as a marketing tool.

참고문헌 (16)

  1. "국회회의록 제289회-법제사법 제7차", ~
  2. 이봉의, "보건의료산업 리베이트관행의 경쟁법적 쟁점과 과제", 서울대학교 법학, 50(4), pp.195~220 (2009), 법학연구소
  3. "의료법 제3조", ~
  4. 홍명수, "독점규제법상 리베이트 규제의 검토", 법과사회, (34), pp.373~393 (2008), 법과사회이론학회
  5. 조성국, "보건산업에 대한 독점규제법의 적용에 관한 연구 - 제약산업 리베이트 규제의 최근동향을 중심으로 -", 경쟁법연구, 22, pp.286~306 (2010), 한국경쟁법학회
  6. 이하영, "의약품 리베이트 자율규제의 한계: 제도론적 접근", 행정논총, 49(1), pp.139~165 (2011), 한국행정연구소
  7. 정인석, "약제비 관리방안으로서 저가구매 인센티브 제도", 보건사회연구, 29(2), pp.243~267 (2009), 한국보건사회연구원
  8. 공정거래위원회, "10개 제약회사의 부당고객유인행위, 재판매가격유지행위 등 시정조치", ~ (2007)
  9. 양봉민, "보건경제학" (1999)
  10. "공정거래위원회 심의결 제2009-269호, 2009.12. 사건번호 2009서경1250", ~
  11. 보건복지가족부, "2010년 2월 16일 보도자료", ~
  12. "의료기기법 제13조 제3항", ~
  13. 이수기, "의약품 리베이트 근절을 위한 입법적 대책", 이슈와 논점, (52), pp.3~ (2010), 국회입법조사처
  14. "공정위 의결 제2007-562호", ~
  15. "공정위 의결 제2007-552호", ~
  16. "공정위 의결 제2007-553호", ~ (2007)

관련 논문AI추천

이 간행물의 다른 논문 (37건)